Questionnaires Relating to the Transmission of Drug Information Regarding the Interaction of Sorivudine.
スポンサーリンク
概要
- 論文の詳細を見る
Between September and November 1993, 15 people died due to the interaction between sorivudine (anti-virus drug: commercial name is Usevir) and fluorouracil analogs (anti-tumor drug). Questionnaires were completed by the physicians who had opportunities of prescribing fluorouracil analogs as part of post-marketing randomized clinical trials at that time. Two types of questionnaires were designed. One questionnaire was regarding the doctor's general recognition of interactions among drugs. The other questionnaire asked doctors about their specific action concerning individual patients. Questionnaires were collected from 270 doctors covering about 610 patients; 87.8% of the doctors had already been informed of the interaction between sorivudine and fluorouracil analogs. Newspapers (48.5%) were the largest source of information. Only 2.5% of the doctors acquired their information from the package insert with the drugs. Of the doctors questioned, 51.2% had the possibility to administrate the drug even though "combination should be avoided" was printed on the drug package insert. The 2nd questionnaire about the actions of the doctors showed that in 44.8% cases doctors checked whether sorivudine was used in any way and in 47.7% of cases doctors did not check at all.<BR>There are several points regarding the tragedy of sorivudine. The factors related to this tragedy include the system to check the interaction between drugs, telling patients the truth about cancer, and patient consultation regarding medication. These problems originate from the Japanese system of tansmission of drug information. The results of the present survey indicate that it is very difficult to detect drug interaction, to transmit this information to doctors and to inform patients in today's Japanese system. The possibility of a second sorivudine tragedy cannot be denied.
- 一般社団法人 日本臨床薬理学会の論文
著者
-
大橋 靖雄
東京大学医学系研究科・健康科学・看護学専攻
-
浜田 知久馬
東京大学医学部
-
浜田 知久馬
東京大学医学部薬剤疫学
-
小出 大介
東京大学医学部附属病院中央医療情報部
-
楠 正
東京大学医学部薬剤疫学
-
小出 大介
東京大学医学部保健社会
-
大橋 靖雄
東京大学医学部健康科学・看護学科疫学・生物統計学
関連論文
- 終日ウロフローメトリによるIPSSの信頼性の検討
- インスリン非依存型糖尿病における血管合併症の疫学的研究(第5報)-初診時における心電図*血性変化の頻度と危険因子-
- 表在性膀胱腫瘍に対する Adriamycin 再発予防膀胱腔内注入療法第4次研究(術前注入療法の再発予防効果)結果報告
- D-13 非小細胞肺癌患者を対象としたLY188011(塩酸ゲムシタビン)とシスプラチンとの併用パイロット試験(3週スケジュール)Gemcitabine Japan lung Cancer Study Group
- 原発性骨粗鬆症の診断基準(2000年度改訂版)
- 膀胱発癌リスクと乳酸菌の習慣的摂取 : 症例 : 対照比較研究による疫学的検討
- 表在性膀胱癌のTURBT後再発予防治療におけるEpirubicin膀胱内注入の臨床試験
- Epirubicinによる表在性膀胱癌のTUR-BT術後再発予防効果(NUORG SBT-004)
- A-5 新規抗癌剤TOP-53の第一相試験
- 臨床試験に対する生物統計学の社会的貢献 : 4半世紀の経験と今後の展望